Introduction: Whether the liver first approach is beneficial in patients with multiple bilobar synchronous colorectal liver metastases (CLM) undergoing one-stage hepatectomy (OSH) remains to be demonstrated. The aim of this study was to assess the feasibility and outcome of the liver-first approach for patients with synchronous CLM receiving OSH. Methods: Between 2012 and 2016, 210 patients with multiple bilobar (4) CLM, of which at least one in contact with firstor second-order portal branches and/or with hepatic vein at caval confluence, underwent OSH. Of these, 19 (9%) patients underwent the liver-first approach as approved by our multidisciplinary team. All patients received perioperative system chemotherapy and had partial response or stable disease. Results: The median CLM number and size were 12 (range 5-45) and 3.7 (0.7-17 cm) respectively. The location of the primary tumor was in the rectum in 5 (26%) and in the colon in 14 (74%) patients. The median chemotherapy courses were 11 (range 4-16). The strategy was completed in 18 patients (95%). One patient developed hepatic disease progression. 90-day postoperative morbidity and mortality were 26% and 0% after liver resection and 19% and 0% after colorectal resection. After a median follow-up of 19 months (range 6-33), the intention-to-treat 2-year overall survival was 40% (Figure) . Twelve (63%) patients developed disease recurrence. Conclusions: The liver-first approach is safe and feasible in most of the patients with advanced synchronous CLM. Despite a high rate of disease recurrence, acceptable overall survival may be achieved.
EP01A-030 OUTCOME OF HEPATECTOMY FOLLOWING CHEMOTHRAPY FOR SYNCHRONOUS LIVER METASTASIS OF COLORECTAL CANCER Y. Senda, Y. Shimizu and S. Natsume Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, Japan
Background: In our department, we re-evaluate surgical indication after 3 months watchful waiting following resection of primary lesion for patients with resectable synchronous liver metastasis of colorectal cancer (sCRLM) to avoid unnecessary hepatectomy in consideration of occult metastatis.
On the other hand, chemotherapy is administered for patients with sCRLM that is unresectable or not suitable for hepatectomy prior to the hepatectomy. The aim of this study is to evaluate outcome of hepatectomy following chemotherapy for sCRLM Methods: Between April 2006 and March 2016, 141 consecutive sCRLM patients who underwent primary tumor resection at our department. 44 patients underwent hepatectomy alone (S-group), 23 patients underwent hepatectomy following chemotherapy (CS-group), 74 patients were treated with chemotherapy alone (C-group). Results: Although tumor diameter was similar between Sgroup and CS-group, the number of liver metastasis was more in CS-Group than S-group. Duration of surgery, blood loss, weight of resected liver, post-operative hospital stays, rate of R0 resection and serious postoperative complications was not different between S-group and CS-group (Table) . Overall survival (OS) of S-group and CS-group was similar, and better than C-group (3-years survival rate: 89.9% vs 85.6% vs 40.0%).In CS-group, relapse-free survival) was much better in patients with ETS (early tumor shrinkage) than in those with non-ETS ( Figure) . Conclusion: Although CS-group had more number of liver metastasis, Hepatectomy following chemotherapy was performed with the safety and prognosis equivalent to hepatectomy without chemotherapy. ETS may be a useful indicator of hepatectomy during chemotherapy in sCLM patients.
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Y. Kotera, S. Ariizumi, A. Omori, S. Yamashita and M. Yamamoto Surgery, Tokyo Women's Medical University, Japan
The assessment for PET negative nodules has not been determined yet. We try to determine the role of the PET negative nodules for the patients of colorectal liver metastasis. (subjects and methods) 126 patients who underwent PET before hepatectomy at our hospital between 2005 and 2017. In these cases, the effect of NAC, the disease free survival rate (DFS) and overall survival rate (OS) were examined, and the characteristics were compared and investigated in 49 patients who underwent NAC and 77 cases who didn't receive NAC. (Results) Electronic Posters (EP01A-EP01E) -Liver S343
